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Most DNA vaccines rely on strong viral promoters to optimize levels of transgene expression. Some studies have demonstrated that the
potency of viral promoters does not necessarily correlate with DNA vaccine efficacy in vivo. This has partly been attributed to downregulation of
these promoters by cytokines such as interferon g induced by the CpG motives of these vaccines. In an attempt to avoid downregulation of viral
promoters by IFN-g, we tested vaccine vectors driven by the MHC class II promoter. To enhance the activity of this promoter, another plasmid
expressing the human MHC class II transactivator driven by a viral promoter, the native IFN-g inducible CIITA type IV promoter (PIV) or a
synthetic promoter containing IFN-g inducible elements was co-inoculated. Our data show that a non-viral promoter such as the MHC class II
promoter tested in this study can indeed be used in DNA vaccines.
D 2005 Elsevier Inc. All rights reserved.Keywords: DNA vaccine; IFN-g; Rabies; HIVIntroduction
Over the past decade, plasmid DNA has been used
extensively for gene transfer into mammalian cells. When
used as vaccines in small experimental animals, plasmid DNA
induces protective T- and B-cell-mediated immune responses
against a range of pathogens including viruses (Whalen et al.,
1995; Xiang et al., 1994). Nevertheless, DNA vaccines thus far
have performed poorly in clinical trials. The magnitude of
immune responses generated by a vaccine in part depends on
the antigenic load. Levels of antigen expression by genetic
vaccines, such as plasmid vectors, are dictated by the strength
of transcriptional regulatory elements and by the transduction
efficiency of the plasmid. Most DNA vaccines use strong viral
promoters to optimize transgene product expression (Norman
et al., 1997; Oran and Robinson, 2003; Xiang et al., 1994).
Induction of primary adaptive immune responses does not
solely depend on foreign antigen but also requires the antigen
to be presented in lymphatic tissues by mature dendritic cells
expressing co-stimulatory molecules. Immature dendritic cells
are dispersed throughout an organism where they can be
transduced by plasmid vectors. The bacterial DNA sequences0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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which are rare or methylated in mammalian DNA. These
sequences are recognized by pattern recognition receptors of
the Toll-like receptor (TLR) family, i.e., TLR-9 expressed by
cells of the innate immune system as pathogen-associated
molecular patterns (Agrawal and Kandimalla, 2003). Interac-
tion of unmethylated CpG sequences with TLR-9 triggers an
inflammatory reaction, which results in the release of pro-
inflammatory cytokines, such as interferons (IFN), IL-12, IL-6
and TNF-a, and in maturation of dendritic cells (Hemmi et al.,
2000). Presence of such motifs is essential for the immunoge-
nicity of DNAvaccines, and elimination or methylation of CpG
motifs prevents DNA vaccine-induced activation of adaptive
immune responses (Pasquini et al., 1999; Reyes-Sandoval and
Ertl, 2004).
IFN released rapidly in response to bacterial DNA by the
innate immune system has antiviral activity. IFN-g enables cells
to resist viral replication, in part by inhibiting transcription of
viral genes. IFN-g down-modulates propagation of viruses by a
number of pathways such as by the IFN-g-induced production of
transcriptional repressors, which bind to IFN responsive
enhancer elements within viral promoters (Darnell et al., 1994;
Gribaudo et al., 1993). Thus, although CpG-induced inflamma-
tory responses are essential to drive an adaptive immune
response to DNAvaccines, the resulting cytokines may dampen6) 412 – 420
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cells as was shown previously, where under certain experimental
conditions increase of IFN-g production reduced the immune
response to a DNA vaccine (Xiang and Ertl, 1995).
To test if vectors based on promoters that are rendered more
active in presence of IFN-g can provide an alternative to
currently used DNA vaccines based on strong viral promoters,
we developed DNA vaccines containing the MHC class II
promoter. The MHC class II promoter requires induction by the
MHC class II transactivator (CIITA), which can be upregulated
by IFN-g. Here, we show that DNA vaccines encoding the
rabies virus glycoprotein or a truncated codon-optimized form
of the HIV-1 gag protein under the control of the MHC class II
Ea promoter combined with vectors encoding CIITA induce
robust transgene product-specific adaptive immune responses
in mice, which are increased in the presence of IFN-g.
Results
Transgene product expression by vectors
DNA vaccine vectors that were used in this study are listed
in Table 1. The pCII vectors had been generated previously by
replacing the SV40 promoter of the commercially available
pSG5 vector with the MHC class II E2a promoter. In the
pPIV.CIITA vector, expression of CIITA is driven by the CIITA
type IV promoter known to be upregulated by IFN-g. In the
pRep4.CIITA vector, expression is driven by the RSV
promoter, which is downregulated by IFN-g. The promoter
controlling expression in the pEn.CIITA vector was designed
by us to contain IFN-g-responsive elements which should
result in enhanced promoter activity in presence of this
cytokine. PCR (following conversion of mRNA to cDNA)
was performed to confirm expression of CIITA in L929 cells
transfected with pRep4.CIITA, pPIV.CIITA or pEn.CIITA
vectors. Briefly, 48 h following transfection of L929 cells with
these plasmids, RNA extraction was performed on the
transfected cells using Tri Reagent (Sigma, MO), and samples
were then subjected to DNase treatment to remove contami-
nating DNA prior to cDNA synthesis using M-MLV reverse
transcriptase (Invitrogen, CA). CIITA cDNA was detected by
RT-PCR using previously described primers (Pai et al., 2002)
(results not shown). Plasmid pCIIrab.gp has been tested for in
vitro expression previously (Xiang et al., 1997). To confirm
gag37 expression by pCII.gag37, NIH 3T3 cells were
transfected with this plasmid, and gag37 protein expressionTable 1
List of plasmid vaccines used in this study
Plasmid Promoter Transgene
pSG5rab.gp SV40 Rabies glycoprotein
pCIIrab.gp MHC class II Rabies glycoprotein
pRep4.CIITA RSV Class II transactivator
pEn.CIITA Synthetic promoter
containing IFN-g
inducible elements
Class II transactivator
pPIV.CIITA CIITA promoter IV Class II transactivator
pCII.gag37 MHC class II Truncated HIV-1 gagwas detected by Western Blot using previously described
methods (Pinto et al., 2003) (results not shown).
Effect of IFN-c on viral promoter function
Cell lysates from L929 cells transfected with pSG5LacZ
vector with and without IFN-g treatment were subjected to a h-
galactosidase assay (Fig. 1). Results from this assay clearly
demonstrated that the activity of the SV40 promoter in
pSG5LacZ was significantly compromised in the presence of
IFN-g; with increasing doses of IFN-g, there was a
corresponding decrease in the level of h-galactosidase expres-
sion. Comparable results were obtained with vectors expressing
the rabies virus glycoprotein (data not shown).
Immune responses to rabies glycoprotein
Vectors were initially analyzed for induction of transgene
product-specific B cell responses. Groups of C3H/He mice (5
per group) were injected into the quadriceps muscles with
pCIIrab.gp combined with pEN.CIITA, pPIV.CIITA, pRe-
p4.CIITA or as a control with an empty vector. Additional
control mice were injected only with the pEn.CIITA vector and
an empty vector. Animals were bled 2, 4 and 6 weeks post-
immunization, and antibody titers were determined by an
ELISA. None of the groups had detectable antibodies to rabies
virus by 2 weeks after vaccination (not shown). By 4 weeks
following immunization, mice injected with both pCIIrab.gp +
pEn.CIITA vectors or pCIIrab.gp + pRep4.CIITA vectors
mounted a vigorous antibody response. Mice vaccinated with
either pCIIrab.gp vector alone or pCIIrab.gp + pPIV.CIITA
vectors had only marginal titers of rabies virus-specific
antibodies by week 4 which slightly increased by week 6 in
mice that received the pPIV.CIITA + pCIIrab.gp vectors (Fig.
2). The experiment was repeated by assessing antibody titers
by a neutralization assay (Table 2). In this experiment, a vector
expressing the rabies virus glycoprotein under the control of
the SV40 promoter was included. This vector has been studied
extensively in comparison to other vectors with different
regulatory sequences or different CpG contents and consis-
tently outperformed other DNA vaccines to the rabies virus
glycoprotein. Rabies virus neutralizing antibody titers were
measured against a reference serum from the World Health
Organization to allow for expression of titers in International
Units, which can be used as a surrogate measure for protective
immunity; titers of or above 0.5 IU are known to protect
against a peripheral infection with an otherwise lethal dose of
rabies virus. Co-injection of pCIIrab.gp + pRep4.CIITA vectors
resulted in antibody titers above 0.5 IU by week 2, which
increased further by week 4. Co-injection of pCIIrab.gp +
pEn.CIITA vectors achieved protective titers of antibodies to
rabies by week 4. Injection of pCIIrab.gp or pCIIrab.gp +
pPIV.CIITA vectors failed to induce neutralizing antibody titers
of or above 0.5 IU. This indicates that the transactivator is
essential to optimize stimulation of antibody responses to the
DNA vaccine containing the MHC class II promoter. Results
furthermore show that the CIITA promoter IV is not as
Fig. 2. Rabies virus glycoprotein-specific antibody response at 4 and 6 weeks
following a single administration of DNA vaccine. Groups of C3H/He mice
were immunized with pCIIrab.gp vector alone (hatched squares), pCIIrab.gp
and pEN.CIITA vectors (solid squares), pCIIrab.gp and pPIV.CIITA vectors
(half shaded squares), pCIIrab.gp and pRep4.CIITA vectors (squares with a
cross) or pEn.CIITA vector only (open squares). Data are shown as mean T SD
for triplicate samples. Data were analyzed using a Student t test. The x and y
axes of each graph were normalized to the values/parameters shown to the lef
and at the bottom. The antibody response in mice immunized with the
pCIIrab.gp and pEn.CIITA vector regimen was significantly higher than tha
obtained with the other vaccination regimens (P  0.05) except for both
pCIIrab.gp and pRep4.CIITA vectors. There was no significant difference
between the mice immunized with pCIIrab.gp and either pEn.CIITA vector o
pRep4.CIITA vector.
Fig. 1. Effect of IFN-g on function of viral promoters. L929 cells transfected
with plasmid pSG5LacZ were treated with 100 U/ml, 50 U/ml or 1 U/ml of
IFN-g. Following a 48 h incubation, lysates were obtained from these cells and
a h-galactosidase assay performed. Data are shown as mean T SD for triplicate
samples. With increasing amounts of IFN-g, less LacZ expression was detected.
The highest expression levels were detected in the samples that had been
transfected with pSG5LacZ without IFN-g treatment (*the absorbance of these
samples were greater than 3 and consequently too high to be measured using
this spectrophotometer).
Table 2
Virus neutralizing antibody (VNA) titers to rabies virus determined at 2, 4 and
8 weeks following immunization with various vaccine constructs
Vaccine VNA titer (2–8 weeks following
immunization) (IU/ml)
2 weeks 4 weeks 8 weeks
pCIIrab.gp <0.5 <0.5 <0.5
pEn.CIITA <0.5 <0.5 <0.5
pSG5rab.gp 4 20 16
pEn.CIITA + pCIIrab.gp <0.5 3 6
pPIV.CIITA + pCIIrab.gp <0.5 <0.5 <0.5
pRep4.CIITA + pCIIrab.gp 2 6 4
VNA titers over 0.5 IU confer protection against rabies virus infection.
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the synthetic promoter pEn in achieving significant levels of
CIITA expression. Near equal performance of the CIITA
vectors containing the IFN-inducible artificial promoter or
the RSV promoter (the latter which would be downregulated
by IFN-g) may reflect differences in the relative strengths of
these regulatory elements that are equalized in the presence of
IFN-g. Alternatively, even small amounts of CIITA may suffice
to saturate the system and achieve maximal activation of the
MHC class II promoter. The pSG5rab.gp vector induced the
highest antibody response.
T cell responses assessed by measuring cytokine release
from in vitro stimulated splenocytes mirrored antibody
responses, although the response to the pSG5rab.gp vector
was only marginally higher that the response to the pCIIrab.gp +
pEn.CIITA or pCIIrab.gp + pPREP4.CIITA vectors. Spleno-
cytes of mice immunized with both pCIIrab.gp and pEn.CIITA
or pRep4.CIITA secreted significant and comparative levels of
IL-2/IL-4 and IFN-g in response to rabies virus, while cytokine
production from splenocytes of mice immunized with pCII-
rab.gp + pEn.CIITA vectors or pCIIrab.gp + pRep4.CIITA
vectors secreted detectable but significantly lower levels of
cytokines (Fig. 3). Splenocytes of mice immunized with
pSG5rab.gp secreted slightly higher levels of IFN-g compared
with all other groups, while proliferative responses were
comparable. To assess if indeed the artificial promoter pEn
was influenced by IFN-g in vivo, we immunized groups of
IFN-gamma knockout (GKO) mice and control C57BL/6 mice
with pCIIrab.gp and pEn.CIITA or pEn.CIITA (Fig. 4A). Nott
t
rsurprisingly, GKO mice immunized with pCIIrab.gp +
pEn.CIITA vectors exhibited a lower antibody response than
the control mice immunized with the same vaccines. Impor-
tantly, there was no significant difference in the immune
response between GKOmice immunized with both pCIIrab.gp +
pEn.CIITA vectors, or pCIIrab.gp + pEn.CIITA vectors,
confirming that, in the absence of IFN-g, the function of
promoter pEn and consequently the performance of the MHC
class II promoter-driven pCIIrab.gp vector is severely com-
promised. The pSG5rab.gp vector induced higher antibody
Fig. 3. Cytokine release from splenocytes 6 weeks following immunization
with various plasmids. Splenocytes were incubated with 1 Ag ERA-BPL (black
bars) or media (white bars) for 48 h and the supernatants obtained for cytokine
testing. Top graph: supernatants were tested for the presence of IFN-g. Bottom
graph: supernatants were tested for induction of HT-2 cell proliferation (IL-2/
IL-4 detection). Mice immunized with pSG5rab.gp vector demonstrated the
highest immune response. However, mice immunized with pEn.CIITA +
pCIIrab.gp vectors had a significantly higher IL-2/IL-4 and IFN-g response
than mice immunized with pEn.CIITA vector only, pCIIrab.gp vector only or
both pEn.CIITA and pPIV.CIITA vector (P  0.05). There was no significant
difference in the cytokine responses between mice immunized with pCIIrab.gp
vector and either pEn.CIITA or pRep4.CIITA vectors.
Fig. 4. The rabies virus glycoprotein-specific immune response at 4 and 8 weeks
following a single administration of DNA vaccine. Groups of GKO mice
(bottom panel) and C57BL/6 mice (top panel) were immunized in panel Awith
pCIIrab.gp and pEN.CIITA vectors (solid squares) or pEn.CIITA vector only
(open squares) in panel B or with pSG5rab.gp vector (solid squares) or as a
control pEn.CIITA vector (open squares). Data are shown as mean T SD for
triplicate samples. Data were analyzed using a Student’s t test. There was a
higher antibody response detected in C57BL/6 mice immunized with both
pCIIrab.gp and pEN.CIITA vectors compared with mice immunized with only
pEn.CIITAvector (P  0.01). No significant difference in the immune response
was observed in GKO mice immunized with pCIIrab.gp + pEN.CIITA vectors
or only pEn.CIITA vector at either 4 weeks or at 8 weeks post-immunization.
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indicating that under certain experimental conditions IFN-g
indeed can dampen the antibody response to a DNA vaccine’s
transgene product controlled by a viral promoter.
Levels of expression of transcripts in vivo
To further evaluate the effect of IFN-g on antigen
production by the CIITA-induced MHC class II promoter, we
determined copy numbers of vector and vector-derived
transcripts in muscles and lymph nodes of C57BL/6 and
GKO mice injected with pCIIrab.gp alone or with pCIIrab.gp +
pEN.CIITA. Groups of 5 mice were injected with the various
vectors, and the injected muscles and their draining lymph
Table 3
Induction of HIV gag-specific IFN-g producing CD8+ T cell response in the
spleen
Vaccine CD8+ T cell response following immunization (%)
8 weeks after
prime
14 days after
homologous boost
with DNA vaccine
7 days after boos
with 109 vp
AdHu5gag37
pCII.gag37 0.28 T 0.12 0.83 T 0.03 6.3 T 2.02
pEn.CIITA 0.01 T 0.01 0.01 T 0.008 0.44 T 0.2
pCMVgag37MI-10D 0.55 T 0.08 1.55 T 0.5 10.39 T 0.69
pCII.gag37 +
pEn.CIITA
0.47 T 0.05 1.06 T 0.11 8.14 T 3.4
Percentage of IFN-g positive CD8+ T cells in the spleen 8 weeks following a
DNA vaccine prime, 14 days following homologous boost with DNA vaccine
or 7 days following boost with 109 vp AdHu5gag37. Data are shown as the
means of two separate experiments T SD. Highest response was observed in
mice immunized with pCMVgag37M1-10D ( P  0.05). However, there was
no statistically significant difference in the response generated in mice
immunized with pCMVgag37M1-10D or pCII.gag37 and pEN.CIITA when
boosted with DNA vaccine or AdHu5gag37.
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individual mice were analyzed for the presence of sequences of
the rabies virus glycoprotein gene by a real-time PCR. DNA in
muscle and DNA and cDNA from lymph nodes could not be
reliably detected by a real-time PCR in a significant number of
the samples, therefore these data were not included in this
study. The analysis of cDNA from the muscle samples showed
some variability in the amounts detected between individual
mice of a given group. Nevertheless, significantly higher (P 
0.05) copy numbers of rabies glycoprotein mRNA copies could
be detected in muscle from pCIIrab.gp + pEn.CIITA co-
immunized C57BL/6 mice than in the similarly vaccinated
GKO mice, indicating that IFN-g was essential to upregulate
the promoter in pEn.CIITA as in its absence expression of
rabies virus glycoprotein transcripts from the pCIIrab.gp vector
was markedly lower (Fig. 5). The lowest amount of mRNAwas
detected in both C57BL/6 and GKO mice injected with
pCIIrab.gp only. Samples from control animals that were not
injected with a vector containing the rabies virus glycoprotein
were negative in all experiments.
Responses to HIV-1 gag
To evaluate the vaccines for induction of CD8+ T cell
responses, we used a codon-optimized gene encoding aFig. 5. Quantification of mRNA in muscle by real-time PCR using
oligonucleotide primers that amplify the rabies glycoprotein gene (Reyes-
Sandoval and Ertl, 2004). RNAwas isolated from muscle tissue obtained from
C57BL/6 mice and interferon g knockout (GKO) (B6.129S7-Ifngt) (*) mice 72
h following IM vaccination with pCIIrab.gp vector, both pCIIrab.gp and
pEn.CIITA vectors or pEn.CIITA vector only. Data shown are the number of
copies of rabies glycoprotein gene per 106 copies of the housekeeping gene
graph. Rabies glycoprotein mRNA was not detected in the mice injected with
pEn.CIITA vector only. The amount of rabies glycoprotein mRNA detected in
C57BL/6 mice injected with pCIIrab.gp and pEn.CIITAvectors was higher than
in GKOmice injected with the same vaccines (P  0.05). C57BL/6mice injected
with pCIIrab.gp and pEn.CIITAvectors had higher levels of rabies glycoprotein
mRNA than those given only pCIIrab.gp vector (P  0.05). There was no
significant difference in the amount of mRNA detected in GKO and C57BL/6
mice immunized with pCIIrab.gp vector only. Means are indicated by X.ttruncated from of the gag gene of HIV-1 for which an
immunodominant CD8+ T cell epitope has been identified for
mice of the H-2d haplotype. Splenocytes of BALB/c mice
vaccinated with pCII.gag37 vector alone or with pCII.gag37 +
pEn.CIITA vectors and mice injected with pEn.CIITA vector
alone (negative control) or pCMVgag37M1-10D vector (a
positive control vector in which the transgene product is driven
by the CMV promoter) were tested for frequencies of gag-
specific splenic CD8+ T cells by intracellular cytokine staining
for IFN-g 8 to 10 weeks later. Frequencies in mice immunized
with pCII.gag37 + pEn.CIITA vectors were approximately 1.5-
fold higher than those obtained from mice immunized with
pCII.gag37 only (Table 3). This result is in contrast to data
obtained in the rabies virus system where induction of
transgene product-specific antibodies by the pCII.rab.gp vector
required addition of a vector expressing CIITA. There was no
statistically significant difference in the magnitude of the CD8+
T cell response elicited by pCMVgag37M1-10D or pCII.gag37
+ pEn.CIITA vectors. In all groups, frequencies of gag-specific
IFN-g producing CD8+ T cells increased upon a second
immunization with the same vector or an unrelated viral vector,
i.e., an E1-deleted adenovirus vector of the human serotype 5
expressing gag 37. Not surprisingly, the increase in DNA
vaccine boosted mice was not as high as that observed in mice
boosted with recombinant adenovirus. Upon booster immuni-
zation with either DNA or the AdHu5gag37 vector, differences
in frequencies of gag-specific CD8+ Tcells achieved by priming
with pCII.gag37 with or without pEn.CIITA became less
pronounced.
Discussion
Although DNA vaccines induce protective immunity in
experimental animals, they thus far have lacked efficacy in
humans. The DNA vaccine’s inability to induce robust immune
responses in humans may reflect recently described differences
in the immune systems of mice and humans such as those of
TLR expression patterns in distinct subsets of dendritic cells
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differ especially upon intramuscular administration of DNA
vaccines where the inoculation volume used for rodents cannot
be increased proportionally to the weight and body mass of a
human (that is, 0.1 ml for a 20 g mouse would translate into
300 ml for a 60 kg human). In mice, immune responses to
DNA vaccination decrease upon reduction of the inoculation
volume, indicating that the pressure associated with injection of
a relatively large amount of fluid may facilitate transduction or
alternatively may cause tissue damage that promotes activation
of the innate immune system. DNA vaccines may achieve
lower antigenic loads in humans due to impaired transcription.
Various studies have clearly demonstrated that the use of viral
promoters generally does not achieve long-term high level gene
expression in vivo, even when substantial amounts of DNA are
used. One of the reasons for this is promoter extinction (Qin et
al., 1997). As our studies and the work of other researchers
show, cytokines such as TNF-a and particularly IFN-g, which
are released as part of an innate immune response to the
inoculated plasmids, play a role in the downregulation of viral
promoters at both the transcriptional and posttranscriptional
level in vivo (Gribaudo et al., 1993; Kerr and Stark, 1992).
IFN-g interference on a viral promoter may be more
pronounced in hosts such as humans that unlike experimental
mice are not maintained in a controlled laboratory environ-
ment, which is relatively free of pathogens. Consequently,
these hosts may have a range of underlying infections that
promote cytokine production resulting in decreased antigen
production by DNA vaccines. Some eukaryotic promoters such
as the MHC class II promoter are not downregulated by IFN-g.
Previous studies have shown that the MHC class II promoter is
relatively weak (Xiang et al., 1997) and requires activation by
CIITA (Mach et al., 1996). CIITA transcription can be
upregulated by IFN-g, LPS and IL-4 (Harton and Ting,
2000; Ting and Trowsdale, 2002). CIITA enhances MHC class
II expression by coordinating the activity of a range of
transcription factors including NF-Y and CREB (Zhu et al.,
2000). In some cells such as B cells and immature dendritic
cells, CIITA is constitutively produced, in endothelial cells,
fibroblasts and presumably muscle cells, CIITA production
may be induced by IFN-g (Steimle et al., 1994). CIITA
production is regulated by either three or four promoters in
mice and humans respectively (Pai et al., 2002). Importantly,
the IFN-g-induced transcription of CIITA is considered to be
mainly facilitated via the CIITA type IV promoter (this
promoter contains a GAS element, E box and IRF 1 and 2
binding sites, all of which are associated with its IFN-g
inducibility) (Muhlethaler-Mottet et al., 1998; Muhlethaler-
Mottet et al., 1997), and it has been shown that IFN-g-induced
CIITA expression precedes the expression of the MHC class II
genes (Morris et al., 2002).
The results of our study clearly demonstrate that signifi-
cant antibody responses to a transgene expressed by an MHC
class II promoter-driven vector are generated when co-
administered with a CIITA expressing vector containing
either a synthetic IFN-g-inducible promoter pEn or a viral
promoter (RSV). In contrast, only a relatively weak antibodyresponse was generated in the absence of co-inoculated
CIITA. Studies in GKO mice further underscore the impor-
tance of IFN-g in the upregulation of pEN, demonstrating
that, in the absence of IFN-g, promoter pEn activity was
adversely affected as indicated by a significant decrease in the
antibody response to the rabies glycoprotein transgene in
these mice when co-inoculated with both pEn.CIITA +
pCIIrab.gp vectors. Immune responses correlated with levels
of antigen expression in muscle, which were increased in
mice injected with pCIIrab.gp upon addition of the pEn.-
CIITA vector. This increase appeared to be strictly dependent
upon IFN-g and was thus not observed in GKO mice that due
to genetic engineering have a loss mutation for this cytokine.
The correlation between levels of transcripts and by inference
antigenic load produced by muscle cells may reflect that the
antibody response to the DNA vaccine is at least in part
driven by antigen that originates from transduced cells
residing close to the site of vector administration. Results
for induction of CD8+ T cell responses to gag differed.
Studies in BALB/c mice demonstrated that priming with both
pCII.gag37+ pEn.CIITA vectors rather than just pCII.gag37
vector alone did not result in a significant increase in levels of
IFN-g expressing CD8+ T cells. Furthermore, when boosted
with the same DNA vaccine and particularly with a viral-
vector-based vaccine (AdHu5gag37), frequencies of gag-
specific CD8+ T cells were high even in mice that had only
been primed with the pCII.gag37 vector. This suggests that
the co-administration of CIITA did not significantly affect the
CD8+ T cell responses in these mice. This may reflect that
naive CD8+ T cells are stimulated primarily by directly
transduced dendritic cells in which endogenous CTIIA
sponsors activation of the vector’s MHC class II promoter.
The plasmid driven by the native CIITA type IV promoter
performed poorly as shown by the lack of strong transgene
product-specific immune responses in mice injected with
pCIIrab.gp + pPIV.CIITA vectors indicating that CIITA
promoter IV may not be active in muscle tissue even in
presence of IFN-g. In summary, our studies show that vectors
based on the MHC class II promoter induce potent immune
responses (particularly B cell responses) in the presence of
CIITA. Traditional DNA vaccines in which transgene product
expression is driven by a strong viral promoter outperformed
these novel vectors in mice at least with regard to induction
of antibody responses. This may in part reflect the use of a
two-vector system in which increased expression of the MHC
class II-promoter driven transgene depends on co-transfection
of cells with the CIITA-expressing vector. A one-vector
system either encoding CIITA and the vaccine antigen under
the control of the MHC class II promoter within a single
vector or a vaccine vector with a promoter that is independent
of a transactivator that shows enhanced activity in the
presence of pro-inflammatory cytokines may result in superior
immune responses. This may render such vaccines useful for
larger species where pro-inflammatory cytokines induced
either by the vaccine vectors or by underlying chronic
infections may have a more substantial impact on the
performance of vectors that are driven by viral promoters.
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Mice
Female 6–8-week-old C3H/He mice and BALB/c mice
were obtained from Charles River (Boston, MA). IFN-g
knockout mice (GKO) strain B6.129S7-Ifngt and C57BL/6
mice were purchased from Jackson Laboratories (Bar Harbor,
Maine). Mice were housed at the Animal Facility of The Wistar
Institute.
Cell culture
Baby Hamster Kidney (BHK), NIH3T3 and L929 cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) in a 10%
CO2 incubator at 37 -C. HT-2 cells, an indicator cell line for
IL-2 and IL-4, were grown in DMEM supplemented with 10%
FBS and 10% rat concanavalin A.
Viruses
Evelyn Rokitniki Abelseth (ERA) strain of the rabies virus
inactivated with h-propionolactone (ERABPL) was used at a
concentration of 0.1 mg/ml. An E1/E3 deleted adenoviral
vector of the human serotpye 5 expressing a truncated form of
gag of HIV-1, termed AdHu5gag37, has been described
previously (Fitzgerald et al., 2003).
Plasmids used in this study
Plasmids pSG5rab.gp and pCIIrab.gp have been previously
described (Xiang et al., 1997). Plasmid pRep4.CIITA was a
generous gift from Dr. P. van den Elsen (Leiden University,
The Netherlands) (Steimle et al., 1993). The MHC class II
transactivator (CIITA) (excised from plasmid pRep4.CIITA)
was inserted into the pSG5.pBlue vector (this vector was
constructed by the insertion of the cloning sites of pBluescript
into the pSG5 vector) (Xiang et al., 1997). The IFN-g inducible
CIITA type IV promoter (PIV) was amplified from the genome
of mouse cells by a polymerase chain reaction (PCR). This
promoter was then cloned into the pSG5.pBlue vector upstream
of the CIITA gene to create plasmid pPIV.CIITA. Plasmid
pSG5LacZ has been described before. To improve efficacy of
PIV while retaining its fundamental IFN-g inducibility, the
IFN-g-responsive elements of CIITA type IV promoter, i.e.,
GAS, IRF-E and E box, were used to generate a hybrid
promoter. The sequence of the mouse PIV containing the GAS
(gamma activation site), IRF1/2 (interferon regulatory sites 1
and 2) and E box was amplified by PCR. Two copies of this
PCR product were inserted in tandem upstream from a minimal
TK promoter (the minimal TK promoter contained transcrip-
tion-associated TATA and GC elements which are not present
in the CIITA type IV promoter) to create promoter pEN.
Promoter pEN and CIITA were then cloned into the
pSG5.pBlue vector to create plasmid pEn.CIITA. Plasmid
pCMVgag37M1-10D was most kindly provided by Dr. G.Pavlakis (National Cancer Institute, Frederick, MD) (Schneider
et al., 1997). Plasmid pCII.gag37 was constructed by inserting
gag37 obtained by PCR amplification from pCMVgag37M1-
10D into the pCII vector downstream from the MHC class II
promoter (Table 1).
In vitro assay to determine LacZ (b-galactosidase) expression
L929 cells were transfected with plasmid pSG5LacZ (LacZ
inserted into the pSG5 vector). Following a 3 h incubation IFN-
g at concentrations of 100 U/ml, 50 U/ml or 1 U/ml was added.
Cells were incubated for another 48 h, and lysates were
obtained from them and tested in a h-galactosidase assay using
standard techniques.
Immunization and bleeding of mice
Mice were inoculated by intramuscular injection of both
hind legs. C3H/He mice immunized with rabies glycoprotein
expressing plasmids were vaccinated with pCIIrab.gp (plasmid
expressing the rabies glycoprotein driven by the MHC class II
promoter) and pRep4.CIITA [plasmid expressing the MHC
class II transactivator (CIITA) driven by the RSV promoter],
pCIIrab.gp alone, both pCIIrab.gp and pPIV.CIITA or pCIIrab.
gp and pEn.CIITA or pSG5rab.gp alone. BALB/c mice
immunized with gag37 expressing plasmids were vaccinated
with pCII.gag37 with and without pEn.CIITA, pEn.CIITA
alone or pCMVgag37M1-10D alone. These mice were boosted
using either DNA vaccine or AdHu5gag37 virus by intramus-
cular injection. GKO (B6.129S7-Ifngt) mice were immunized
with pCIIrab.gp and pEn.CIITA or pEn.CIITA only.
Mice were bled by retro-orbital puncture, and serum was
obtained for antibody determination. All experiments were
repeated between 2 and 4 times. In each experiment, mice were
immunized with 100 Ag of each plasmid, those immunized
with just one plasmid were each also vaccinated with 100 Ag
empty pSG5.pBlue vector (each mouse receiving a total of 200
Ag DNA).
DNA vaccine preparation
Large-scale plasmid preparation was performed using the
Qiagen Mega prep kit (Qiagen, Valencia, CA). Concentration
of DNA was determined by spectrophotometry.
PCR and real-time quantitative PCR (RT-PCR)
Groups of five C57BL/6 and GKO (B6.129S7-Ifngt) mice
were administered pCIIrab.gp, pCIIrab.gp and pEn.CIITA or
pEn.CIITA only by intramuscular injection into both gastroc-
nemius muscles. After 72 h, mice were euthanized, and the
injected muscles and draining lymph nodes (popliteal) were
harvested separately for DNA and RNA extraction using TRI
Reagent (Sigma, MO) following the manufacturer’s protocol.
Samples of mRNAwere subjected to cDNA synthesis using M-
MLV reverse transcriptase (Invitrogen, CA), thereafter, both
DNA and cDNA samples were analyzed by real-time PCR (RT-
T. Vanniasinkam et al. / Virology 344 (2006) 412–420 419PCR) by previously described methods (Reyes-Sandoval and
Ertl, 2004). Data were analyzed using a Student’s t test and
ANOVA.
Virus neutralization assay
Virus neutralizing antibody titers were determined using
BHK-21 cells as described previously (Ertl et al., 1989).
Samples were assayed in duplicate in serial threefold dilutions.
Neutralization titers were determined as the reciprocal of the
serum dilution causing a 50% reduction in the number of cells
infected by the virus.
Enzyme-linked immunosorbent assay (ELISA) for rabies
virus-specific antibodies
The ELISA was performed as previously described (Xiang
et al., 1995). Briefly, microtiter plates were coated with 0.2 Ag/
well of ERA-BPL virus, and dilutions of sera were added.
Following a 1 h incubation, plates were washed, and an
alkaline-phosphatase-labeled secondary antibody was added.
Finally, substrate was added, and IgG concentration was
determined by measuring the optical density in an ELISA
plate reader at a wavelength of 405 nm.
T helper assay
IL-2 or IL-4 released from stimulated splenocytes of
vaccinated mice was detected in a biological assay (Ertl et
al., 1989). Briefly, 6  106 splenocytes were harvested from
each group of mice and grown in the presence of ERA-BPL
antigen or without antigen. Cell-free supernatants were
harvested 48 h later and tested for induction of proliferation
of HT-2 cells (IL-2/IL-4-dependent cell line).
IFN-c assay
Approximately 6  106 splenocytes were harvested from
each group of vaccinated mice and cultured with or without
ERA-BPL antigen. Cell-free supernatants were harvested 48
h later and tested for IFN-g using an ELISA as previously
described (Reyes-Sandoval and Ertl, 2004).
Intracellular cytokine staining
Intracellular cytokine staining was performed as described
previously (Fitzgerald et al., 2003). Splenocytes were stimulated
for 5 h with a peptide containing the H-2d mouse haplotype-
specific immunodominant epitope for HIV gag. Antibodies used
in this assay were a FITC-labeled anti-CD8 and a PE-labeled
anti-IFN-g (BD Pharmingen, San Diego, CA).
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